Welcome to 3i

For US regulatory reasons, US Residents are not to enter this site without the express permission of 3i Group plc, and 3i Group plc is not offering any securities or services in the United States or to US Residents through this site. (The term "US Residents" is defined in the detailed terms and conditions set out in the Terms and conditions page).

I am not a US resident (or I am, but I have 3i Group plc's express permission to use this site) and I accept the terms and conditions.

Terms and conditions

Copy Of Køben Cfc0231

Xellia

  • Sector Healthcare
  • Year invested 2008
  • Location Sweden
  • Status Realised

Xellia is a specialty pharmaceutical group focused on the development, manufacturing and global commercialisation of anti-infective therapies. 

Visit xellia.com

  • Alpharma Oslo Cfc0023
  • Køben Cfa0177

Overview

During our investment period, Xellia transformed from a supplier of niche active pharmaceutical ingredients to a fully integrated speciality pharmaceutical company.

During our partnership, Xellia invested more than $100 million in research and development (‘R&D’) and capacity expansion across its global manufacturing network, including a new fill-finish plant in Copenhagen.

How we added value

  • Platform created for continued growth and enhanced margins, based on a broadened product range and an exciting pipeline of new products
  • Xellia’s focus on R&D resulted in 15 new product filings in 2012
  • Expanded their global manufacturing network including a new fill-finish plant in Copenhagen

3i’s investment and continued support, expertise and commitment has enabled Xellia to successfully grow and transition the business to become leaders in the supply of key anti-infective products.

Carl-Åke Carlsson , Chief Executive and President, Xellia

Regulatory information
This transaction involved a recommendation of 3i Investments plc, advised by 3i Sweden.